Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

ruxolitinib 6Hydroxyurea 3fludarabine phosphate 2bomedemstat 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Injections 2Cyclophosphamide 2Busulfan 2Biopsy 2veliparib 1umbralisib 1piperine 1iadademstat 1givinostat hydrochloride 1givinostat 1fludarabine 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1Transplantation 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1Resistance Training 1Radiotherapy 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycythemia Vera × Panobinostat × 90 days × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡